ONC250117C185000
- 6.90
- 0.000.00%
BeiGene Newsroom
Express News | HKEX: On January 3, JPMorgan's short position in BEIGENE decreased from 1.35% to 0.69%.
Quick Look at the Hong Kong Market | The three major Indices have mixed movements, stocks in Biotechnology and Communication Equipment are rising, ZTE soared by 10%, and BEIGENE increased by over 5%.
Network Technology stocks fell, XIAOMI-W rose by 2.90%, NTES-S rose by 2.19%; most Coal Industrial Concept stocks declined, China Shenhua Energy fell by 3.18%, China Coal Energy fell by 1.69%; most Shipping and Ports stocks decreased, COSCO Shipping Holdings fell by 4.75%, OOIL fell by 3.14%;
Hong Kong stock activity | BEIGENE (06160) rises over 5% as Baizean previously approved a new indication in the U.S. The company's oncology product pipeline is further expanding.
BEIGENE (06160) rose over 5%, as of the time of this report, it increased by 5.16%, trading at 110 Hong Kong dollars, with a transaction volume of 0.147 billion Hong Kong dollars.
Hong Kong stock market midday review | The three major Indexes collectively rebounded! Xiaomi and Tencent rose about 2%; Semiconductors stocks continued to rise, Semiconductor Manufacturing International Corporation rose over 4%.
Network Technology stocks weakened, Bilibili-W fell by 3.60%, XIAOMI-W rose by 2.59%; Sporting Goods stocks performed well, ANTA SPORTS increased by 5.32%, TOPSPORTS dropped by 3.44%; Hong Kong Retail Stocks weakened, BOSSINI INT'L rose by 3.81%, PRADA fell by 2.76%;
UBS Group: Looking ahead at the structural opportunities in the Medical Care Industry in China this year amidst uncertainty, the top picks are INNOVENT BIO (01801.HK), JD HEALTH (06618.HK), WUXI APPTEC (02359.HK), and Eyebright Medical Technology (Beijing
UBS Group published a Research Report stating that last year the Medical Care industry in China faced challenges, impacted by factors such as domestic medical insurance cost control, weak Consumer market conditions, and geopolitical tensions. However, it is expected that by 2025 the Sector risks will trend upward, with Industry valuations and Instituional Holdings levels at historical lows. Coupled with a macro environment that could be more favorable for industry development, investors are expected to find structural opportunities amidst uncertainty. The report indicated that the momentum for biopharmaceutical development continues, with a Bullish outlook on recent CRO profitability, and believes that the fundamentals of various biotech companies are sound. Furthermore, with government support policies for pharmaceutical innovation, it is believed that there will be rapid growth in product sales.
Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
BeiGene Issues Overseas Regulatory Announcement on Form 10-K/A Amendment
10-K/A: Annual report (Amendment)
[Brokerage Focus] CMB International stated that the pharmaceutical industry is expected to outperform the market in 2025, benefiting from overseas interest rate cuts and improvements in the domestic macro environment.
Jinwu Finance News | Zh Xia International released a Research Report stating that on January 3, the General Office of the State Council issued the "Opinions on Deepening the Reform of Pharmaceutical and Medical Instruments Regulation to Promote High-Quality Development of the Pharmaceutical Industry." The policy mentions deepening the reform of the entire process of pharmaceutical and medical instruments regulation, accelerating the establishment of a unified national market in the field of pharmaceutical and medical instruments, creating an innovative ecosystem with Global competitiveness, and promoting the transition of China from a major pharmaceutical country to a strong pharmaceutical country. The policy aims for significant improvements in the quality and efficiency of the review and approval of Innovative Drugs and medical instruments by 2027, establishing a regulatory system that aligns with pharmaceutical innovation and industrial development. By 2035, the pharmaceutical industry will have...
BEIGENE issued 0.5429 million ordinary shares due to the exercise of stock options.
BEIGENE (06160) announced that the company will issue 0.5429 million ordinary shares due to a Director exercising stock options on January 8, 2025.
BEIGENE (06160.HK) issued 0.5429 million shares due to the Director exercising stock options.
Gelonghui reported on January 8 that BEIGENE (06160.HK) announced the issuance of 0.5429 million shares of common stock due to a Director exercising stock options on January 8, 2025.
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene
MAIA And BeiGene Collaborate On THIO's Efficacy In Cancer Treatment
MAIA Biotechnology Announces Clinical Supply Agreement With BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Express News | Maia Biotechnology Announces Clinical Supply Agreement With Beigene for Upcoming Phase 2 Trials in Three Cancer Indications
Hong Kong Stock Market Afternoon Review | All three major indices fell, with the Hang Seng Index down nearly 2%; Network Technology stocks declined, with Tencent down nearly 7% and Xiaomi down over 8%; some mineral stocks rose against the trend, with CGN
Network Technology stocks fell, with XIAOMI-W down 8.13% and TENCENT down 6.79%; Biotechnology stocks declined, with EVEREST MED-B down 6.35% and WUXI BIO down 4.22%; Shipping and Ports stocks weakened, with COSCO Shipping Holdings down 3.47% and CHINA MER PORT down 2.49%.
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
BeiGene Announces Share Options and RSUs Grant to Employees
Beigene (06160) has granted stock options and restricted stock units.
BEIGENE (06160) announced that on December 31, 2024, the Board of Directors' Compensation Committee based on 20...